Drug intelligence / Profile preview

[D-Phe6,β-Ala11,Phe13,Nle14]bombesin(6-14)

Development stage
Unknown
Modality
Peptides
01

Overview

[D-Phe6,β-Ala11,Phe13,Nle14]bombesin(6-14) (also known as BRS-3-AP or BRS-3 agonist peptide-1) is a synthetic peptide and a high-affinity agonist of the bombesin receptor family. It was originally developed by researchers at the National Institutes of Health (NIH) to characterize the pharmacology of the orphan bombesin receptor subtype-3 (BRS-3). While it acts as a pan-bombesin receptor agonist, binding and activating BRS-3, gastrin-releasing peptide receptor (GRPR), and neuromedin B receptor (NMBR) with high affinity, it is widely utilized as a reference tool in research to study BRS-3 signaling pathways and its physiological roles in energy homeostasis, glucose metabolism, obesity, and diabetes.

Other names
BRS-3 agonist peptide-1BRS3 agonist peptide-1BRS 3 agonist peptide-1BRS-3-APBRS3-APBRS 3-APD-Phe6,β-Ala11,Phe13,Nle14]bombesin6-14[D-Phe6,beta-Ala11,Phe13,Nle14]bombesin(6-14)[D-Phe6,beta-Ala11,Phe13,Nle14]bombesin6-14[D-Phe6,β-Ala11,Phe13,Nle14]bombesin(6-14)[D-Phe6,β-Ala11,Phe13,Nle14]bombesin6-14
02

Targets

BRS3 (Bombesin receptor subtype 3)GRPR (Gastrin-releasing peptide receptor)NMBR (Neuromedin B receptor)

Beyond the preview

Go deeper on [D-Phe6,β-Ala11,Phe13,Nle14]bombesin(6-14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [D-Phe6,β-Ala11,Phe13,Nle14]bombesin(6-14).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call